CA2901613C - Dual mek/pi3k inhibitors and therapeutic methods using the same - Google Patents
Dual mek/pi3k inhibitors and therapeutic methods using the same Download PDFInfo
- Publication number
- CA2901613C CA2901613C CA2901613A CA2901613A CA2901613C CA 2901613 C CA2901613 C CA 2901613C CA 2901613 A CA2901613 A CA 2901613A CA 2901613 A CA2901613 A CA 2901613A CA 2901613 C CA2901613 C CA 2901613C
- Authority
- CA
- Canada
- Prior art keywords
- mek
- pi3k
- compound
- structural formula
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361779462P | 2013-03-13 | 2013-03-13 | |
| US61/779,462 | 2013-03-13 | ||
| PCT/US2014/023860 WO2014164942A1 (en) | 2013-03-13 | 2014-03-12 | Dual mek/pi3k inhibitors and therapeutic methods using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2901613A1 CA2901613A1 (en) | 2014-10-09 |
| CA2901613C true CA2901613C (en) | 2020-10-20 |
Family
ID=51659015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2901613A Active CA2901613C (en) | 2013-03-13 | 2014-03-12 | Dual mek/pi3k inhibitors and therapeutic methods using the same |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9611258B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2968345B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6315848B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN105358156A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2901613C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014164942A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2954934C (en) | 2014-06-30 | 2023-09-26 | Glykos Finland Oy | Drug derivative and conjugates |
| US9968604B2 (en) | 2015-04-16 | 2018-05-15 | Chiesi Farmaceutici S.P.A. | Chromene derivatives as phoshoinositide 3-kinases inhibitors |
| US20190038713A1 (en) | 2015-11-07 | 2019-02-07 | Multivir Inc. | Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| EP4086250B1 (en) * | 2016-07-06 | 2024-12-11 | The Regents Of The University Of Michigan | Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same |
| WO2018111902A1 (en) | 2016-12-12 | 2018-06-21 | Multivir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
| JP7350336B2 (ja) * | 2017-08-11 | 2023-09-26 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン | ＭＥＫ／ＰＩ３Ｋ、ＪＡＫ／ＭＥＫ、ＪＡＫ／ＰＩ３Ｋ／ｍＴＯＲおよびＭＥＫ／ＰＩ３Ｋ／ｍＴＯＲの生物学的経路の阻害剤、および治療化合物のリンパ取り込み、生物学的利用能、および溶解性を改善する方法 |
| CN112020510B (zh) | 2018-03-19 | 2024-10-11 | 茂体外尔公司 | 包含用于治疗癌症的肿瘤抑制基因疗法和cd122/cd132激动剂的方法及组合物 |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| WO2021142144A1 (en) * | 2020-01-10 | 2021-07-15 | Immuneering Corporation | Mek inhibitors and therapeutic uses thereof |
| CN111135309B (zh) * | 2020-01-15 | 2023-04-28 | 重庆大学 | 一种核壳结构的替拉扎明药物载体及其制备方法和应用 |
| AR121078A1 (es) | 2020-01-22 | 2022-04-13 | Chugai Pharmaceutical Co Ltd | Derivados de arilamida con actividad antitumoral |
| CN118922183A (zh) * | 2022-01-06 | 2024-11-08 | 医疗免疫工程公司 | Mek免疫肿瘤学抑制剂及其治疗用途 |
| WO2024102859A1 (en) * | 2022-11-09 | 2024-05-16 | Immuneering Corporation | Mek immune oncology inhibitors and therapeutic uses thereof |
| WO2025010287A2 (en) * | 2023-07-03 | 2025-01-09 | Immuneering Corporation | Mek immune oncology inhibitors and therapeutic uses thereof |
| WO2025114495A1 (en) * | 2023-11-28 | 2025-06-05 | Universität Basel | Pi3k inhibitors and use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU2503A (sh) * | 2000-07-19 | 2006-05-25 | Warner-Lambert Company | Oksigenovani estri 4-jodo fenilamino benzhidroksamskih kiselina |
| AR059339A1 (es) * | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| WO2008032060A1 (en) * | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders |
| WO2008032033A1 (en) * | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| WO2009014100A1 (ja) * | 2007-07-20 | 2009-01-29 | Chugai Seiyaku Kabushiki Kaisha | ｐ２７蛋白質誘導剤 |
| JP2011515462A (ja) * | 2008-03-27 | 2011-05-19 | アウククランド ウニセルビセス リミテッド | 置換されたピリミジン、及びトリアジン、並びに癌療法におけるこれらの使用 |
| CA2729914A1 (en) * | 2008-07-11 | 2010-01-14 | Novartis Ag | Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway |
| MX2011010105A (es) | 2009-03-27 | 2012-01-12 | Pathway Therapeutics Inc | Sulfonamidas de pirimidinilo y 1,3,5-triazinilo benzimidazol y su uso en terapia de cancer. |
| AR080945A1 (es) | 2009-07-07 | 2012-05-23 | Pathway Therapeutics Inc | Pirimidinil y 1,3,5-triazinil benzimidazoles y su uso en la terapia contra el cancer |
| US20110166191A1 (en) * | 2010-01-07 | 2011-07-07 | Shijun Zhang | 3-(2-amino-ethyl)-5-(3-cyclohexyl-propylidene)-thiazolidine-2,4-dione and its derivatives as multiple signaling pathway inhibitors and for the treatment of cancer |
| GB201007227D0 (en) * | 2010-04-30 | 2010-06-16 | Univ Basel | Piperazinotriazines |
| EP2651442B1 (en) * | 2010-12-14 | 2020-04-22 | University of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer |
-
2014
- 2014-03-12 CN CN201480014555.XA patent/CN105358156A/zh active Pending
- 2014-03-12 JP JP2016501365A patent/JP6315848B2/ja active Active
- 2014-03-12 US US14/771,233 patent/US9611258B2/en active Active
- 2014-03-12 CA CA2901613A patent/CA2901613C/en active Active
- 2014-03-12 EP EP14779150.3A patent/EP2968345B1/en active Active
- 2014-03-12 WO PCT/US2014/023860 patent/WO2014164942A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN105358156A (zh) | 2016-02-24 |
| EP2968345A4 (en) | 2016-08-17 |
| JP6315848B2 (ja) | 2018-04-25 |
| JP2016516702A (ja) | 2016-06-09 |
| WO2014164942A1 (en) | 2014-10-09 |
| EP2968345A1 (en) | 2016-01-20 |
| US9611258B2 (en) | 2017-04-04 |
| CA2901613A1 (en) | 2014-10-09 |
| US20160002212A1 (en) | 2016-01-07 |
| EP2968345B1 (en) | 2017-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2901613C (en) | Dual mek/pi3k inhibitors and therapeutic methods using the same | |
| AU2021202619B2 (en) | Multifunctional inhibitors of MEK/PI3K and mTOR/MEK/PI3K biological pathways and therapeutic methods using the same | |
| EP2888265B1 (en) | Bivalent inhibitors of iap proteins and therapeutic methods using the same | |
| US20110319362A1 (en) | Stat3 ligands and therapeutic uses thereof | |
| WO2011159685A2 (en) | Inhibition of wdr5 interaction with its binding partners and therapeutic methods | |
| CA2825306A1 (en) | Bcl-2/bcl-xl inhibitors and therapeutic methods using the same | |
| EP4460306A2 (en) | Targeting swi/snf related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 (smarca4) | |
| WO2013082017A1 (en) | Cyclized peptidomimetic small molecule inhibitors of the wdr5 and mll1 interaction | |
| AU2018316175B2 (en) | Inhibitors of MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR and MEK/PI3K3k/mTOR biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20181017 |